Alzheimer-kór: vizsgálatok itt: India
7 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Ahmedabad, Delhi, Hyderabad, Kolkata, New Delhi, Varanasi
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - 3. fázisTaking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Ajmer, Chandigarh, Chhatrapati Sambhajinagar, Hyderabad, Kolkata, Nagpur, Varanasi
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Bengaluru, Hyderabad, Kolkata, Varanasi
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Ajmer, Chandigarh, Hyderabad, Kolkata, Nagpur, Varanasi
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Ahmedabad, Delhi, Hyderabad, Kolkata, New Delhi, Varanasi
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 4. fázisNot yet taking people in IndiaA Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
- Where
- Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi, Tamil Nadu, Vellore
- Életkor
- 60 év to 85 év
- People
- 50
- Run by
- Eli Lilly and Company
See details and how to joinNCT07838155 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Where
- Ahmedabad, Hyderabad, New Delhi
- Életkor
- 55 év to 90 év
- People
- 410 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363